Welcome to our dedicated page for Uniqure news (Ticker: QURE), a resource for investors and traders seeking the latest updates and insights on Uniqure stock.
uniQure (QURE) is a leading biotechnology company advancing innovative gene therapies for severe genetic diseases, including hemophilia and Huntington's disease. This dedicated news hub provides investors and stakeholders with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access the most comprehensive collection of official press releases, clinical trial progress reports, and financial disclosures directly impacting QURE's trajectory. Our curated feed ensures you never miss critical updates about therapeutic advancements or collaborative ventures with industry leaders like Bristol Myers Squibb.
This resource serves investors seeking material events analysis, researchers tracking gene therapy innovations, and healthcare professionals monitoring treatment breakthroughs. All content is sourced from verified channels to maintain accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to uniQure's latest announcements. Check back regularly for real-time updates on one of biotech's most dynamic gene therapy innovators.
uniQure has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AMT-130, for Huntington’s disease. This designation is based on 24-month interim data from Phase I/II clinical trials released in December 2023 and represents a significant milestone.
AMT-130 is the first therapy for Huntington’s disease to receive RMAT designation, facilitating closer collaboration with the FDA and potentially expediting its development and approval process. This decision underscores AMT-130's potential to address the unmet medical needs of Huntington’s disease patients.
uniQure plans to present updated interim data from ongoing Phase I/II studies in mid-2024, including follow-up results on 29 treated patients, 21 of whom will have data spanning at least two years.
uniQure N.V. reported its first quarter 2024 financial results and recent progress, focusing on advancing AMT-130 for Huntington's disease and initiating new Phase I/II trials for Fabry disease, ALS, and MTLE. The company is on track to interact with the FDA in Q2 2024 and reduce expenses to increase shareholder value. Financially, uniQure's revenues increased to $8.5 million, with a cash position of $555.7 million as of March 31, 2024.
FAQ
What is the current stock price of Uniqure (QURE)?
What is the market cap of Uniqure (QURE)?
